Literature DB >> 11493163

Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias.

A M Lipton1, C M Cullum, S Satumtira, E Sontag, L S Hynan, C L White, E H Bigio.   

Abstract

BACKGROUND: Synapse loss has been found to be the major correlate of cognitive decline in Alzheimer disease (AD), and prefrontal synapse loss has been found in patients with frontotemporal dementia (FTD).
OBJECTIVE: To see if our hypothesis that within each FTD case, regional synapse loss would correlate with lateralizing neuropsychologic and neurobehavioral deficits would be correct.
DESIGN: We analyzed synaptophysin as a marker for synapse loss in snap-frozen brain samples, using an enzyme-linked immunosorbent assay technique. Quantitative results were obtained by comparing patient data with a standard curve made by analyzing serial dilutions of a recombinant synaptophysin protein fragment. A board-certified neuropsychologist and a board-certified neurologist, both unaware of the synaptophysin results, determined areas of primary neuropsychologic and neurobehavioral dysfunction. Relationships between areas of primary dysfunction and synapse loss were analyzed using the binomial test. PATIENTS: Six cases of FTD, 28 cases of AD, and 16 nondemented control subjects.
RESULTS: Five of 6 FTD cases had regional synaptophysins correlating with lateralizing frontal or temporal deficits. Three of 6 correlated in 2 or more regions. Although our results were higher than that expected based on a pure-chance mechanism (50% vs 34%), statistical significance was not attained.
CONCLUSIONS: We found a trend for an association between synapse loss and lateralizing neuropsychologic and neurobehavioral deficits in FTD. Studies in larger numbers of FTD cases are planned with the goal of attaining statistically significant conclusions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493163     DOI: 10.1001/archneur.58.8.1233

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  29 in total

Review 1.  Synapse loss in dementias.

Authors:  Ryan Clare; Victoria G King; Martin Wirenfeldt; Harry V Vinters
Journal:  J Neurosci Res       Date:  2010-08-01       Impact factor: 4.164

Review 2.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

3.  p53 prevents neurodegeneration by regulating synaptic genes.

Authors:  Paola Merlo; Bess Frost; Shouyong Peng; Yawei J Yang; Peter J Park; Mel Feany
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

Review 4.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

5.  Sialic Acid within the Glycosylphosphatidylinositol Anchor Targets the Cellular Prion Protein to Synapses.

Authors:  Clive Bate; William Nolan; Harriet McHale-Owen; Alun Williams
Journal:  J Biol Chem       Date:  2016-06-20       Impact factor: 5.157

6.  Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation.

Authors:  Eileen H Bigio; Sandra Weintraub; Rosa Rademakers; Matt Baker; Saman S Ahmadian; Alfred Rademaker; Bing Bing Weitner; Qinwen Mao; Kyung-Hwa Lee; Manjari Mishra; Rakhee A Ganti; M-Marsel Mesulam
Journal:  Neuropathology       Date:  2012-06-18       Impact factor: 1.906

7.  Valosin-containing protein and neurofibromin interact to regulate dendritic spine density.

Authors:  Hsiao-Fang Wang; Yu-Tzu Shih; Chiung-Ya Chen; Hsu-Wen Chao; Ming-Jen Lee; Yi-Ping Hsueh
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

8.  CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Authors:  H Bian; J C Van Swieten; S Leight; L Massimo; E Wood; M Forman; P Moore; I de Koning; C M Clark; S Rosso; J Trojanowski; V M-Y Lee; M Grossman
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

9.  Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration.

Authors:  Clive Bate; Mourad Tayebi; Alun Williams
Journal:  Mol Neurodegener       Date:  2010-04-08       Impact factor: 14.195

10.  Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro.

Authors:  Clive Bate; Mourad Tayebi; Mario Salmona; Luisa Diomede; Alun Williams
Journal:  Neurotox Res       Date:  2009-07-31       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.